Alzamend Neuro, Inc.
NASDAQ:ALZN
Overview | Financials
Company Name | Alzamend Neuro, Inc. |
Symbol | ALZN |
Currency | USD |
Price | 1.65 |
Market Cap | 7,384,361 |
Dividend Yield | 0% |
52-week-range | 1.4 - 20 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Stephan Jackman |
Website | https://www.alzamend.com |
An error occurred while fetching data.
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD